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Cytotoxic Dendritic Cells Generated from Cancer Patients
Daniela Lakomy,*,1 Nona Janikashvili,*,1 Jennifer Fraszczak,* Malika Trad,*
Sylvain Audia,*,† Maxime Samson,* Marion Ciudad,* Julien Vinit,* Catherine Vergely,*
Denis Caillot,‡ Pascal Foucher,x Laurent Lagrost,* Salem Chouaib,{ Emmanuel Katsanis,‖,#,**
Nicolas Larmonier,‖,#,**,2 and Bernard Bonnotte*,†,2
Known for years as professional APCs, dendritic cells (DCs) are also endowed with tumoricidal activity. This dual role of DC as
killers and messengers may have important implications for tumor immunotherapy. However, the tumoricidal activity of DCs has
mainly been investigated in animal models. Cancer cells inhibit antitumor immune responses using numerous mechanisms, includ-
ing the induction of immunosuppressive/ tolerogenic DCs that have lost their ability to present Ags in an immunogenic manner.
In this study, we evaluated the possibility of generating tumor killer DCs from patients with advanced-stage cancers. We demon-
strate that human monocyte-derived DCs are endowed with significant cytotoxic activity against tumor cells following activation
with LPS. The mechanism of DC-mediated tumor cell killing primarily involves peroxynitrites. This observed cytotoxic activity is
restricted to immature DCs. Additionally, after killing, these cytotoxic DCs are able to activate tumor Ag-specific T cells. These
observations may open important new perspectives for the use of autologous cytotoxic DCs in cancer immunotherapy strate-
gies. The Journal of Immunology, 2011, 187: 2775–2782.
D
endritic cells (DCs) play a central role in the initiation
and regulation of innate and adaptive immune responses.
As such, they represent strategic elements of cancer vac-
cination approaches. In response to proinflammatory signals, DCs
generated from patients’ monocytes differentiate into activated
cells that release cytokines and upregulate MHC class I, MHC
class II, and costimulatory molecules. When appropriately loaded
with tumor Ags, DCs are capable of presenting antigenic peptides
and of activating tumor-specific T lymphocytes leading to specific
antitumor immune responses (1). However, to date, only limited
clinical responses have been obtained in trials evaluating the ef-
ficacy of DC-based tumor vaccines (2–7).
The possibility of improving the efficacy of DC-based cancer
vaccines by triggering their direct tumor killing activity has not
been evaluated. Several subsets of killer DCs (KDCs) have been
described in mice (8–14), rats (15–22), and humans (23–49).
However, few data concerning the killing ability of human DCs
generated from cancer patients are available (26, 44, 49). In most
human studies, KDCs were obtained by in vitro differentiation of
monocytes from healthy donors in the presence of GM-CSF and
IL-4 (23, 24, 27, 31, 32, 45, 46) followed by exposure to diverse
inflammatory signals such as IFN-b (35), IFN-g (27), LPS (27, 33,
46), imiquimod, polyinosinic:polycytidylic acid [poly(I:C)] (48),
OK432 (penicillin-inactivated Streptococcus pyogenes) (30), or
CD40L (33). The modes of induction (LPS, CpG, IFNs, and
CD40L) and the effector mechanisms (Fas ligand [FasL], TNF
family members) underlying the killing activity of these cells
remain a subject of controversy (26, 29, 34, 35, 38, 44, 47, 48).
Additionally, the ability of these KDCs to capture dead tumor cells
and to induce specific T cell activation has not been fully eluci-
dated. In terms of clinical applications, triggering of the cytotoxic
activity of autologous DCs from cancer patients may further en-
hance their therapeutic potential by fostering the release of tumor
Ags immediately available for capture and presentation to speci-
fic T cells. Clear evidence has been provided that cancers can in-
hibit the anti-tumor immune response by numerous mechanisms,
including the induction of tolerogenic DCs. However, no infor-
mation regarding the possible negative regulation of KDC cyto-
toxic activity by cancer cells is currently available. To address
this question, in this study we investigated the possibility of gen-
erating human DCs endowed with tumor-killing activity from
cancer patients.
Our results indicate that following activation with LPS, human
monocyte-derived DCs generated from advanced-stage cancer
patients are strongly cytotoxic against tumor cells. These human
KDCs (hKDCs) were capable of triggering necrotic death of a wide
variety of tumor cell lines through direct cell contact. The killing
mechanism involves peroxynitrite release. Interestingly, immature
but not mature DCs exhibit cytotoxic activity against cancer cells.
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Importantly, after killing tumor cells, these cytotoxic DCs were
able to activate tumor Ag-specific T lymphocytes.
Materials and Methods
Cell lines
The following human cancer cell lines were purchased from the American
Type Culture Collection (Manassas, VA): the cervix carcinoma cell line
HeLa, the breast adenocarcinoma cell line MCF7, and the human colorectal
cancer cell lines HT29, SW480, and HCT116. The T1 melanoma cell line
and the LT12 CTL clone specific for the Melan-A25–36 peptide were pro-
vided by Dr. S. Chouaib (INSERM Unite´ 753, Villejuif, France). The
human embryonic cells and the A7R5 rat vascular smooth muscle cells
were provided by Dr. L. Lagrost (INSERM Unite´ 866, Dijon, France).
HT29-expressing GFP was obtained by retroviral transfection (9). The per-
centage of GFP-expressing cells was measured by flow cytometry.
Patients
Ten patients with different confirmed cancers were enrolled in the clinical
study before treatment after giving their written informed consent. Lym-
phoma (n = 2), pulmonary (n = 4), or colon cancer (n = 4) patients at stage
IV incurable cancer were enrolled. None of the patients had received
chemotherapy or any other immunosuppressive treatment during the pre-
vious 3 mo.
Reagents
LPS, flagellin, poly(I:C), gardiquimod, and crystal violet were purchased
from Sigma-Aldrich (St. Louis, MO). 5,10,15,20-Tetrakis(4-sulfonato-
phenyl)prophyrinato iron (III) chloride (FeTPPS) was obtained from Cal-
biochem (San Diego, CA). IFN-g and TNF-a were purchased from Pepro-
Tech (Rocky Hill, NJ), CpG was from InvivoGen (Carlsbad, CA), and
Pam3Cys-SK4 was from EMC (Tubingen, Germany). IL-6 and IL-1b were
purchased from R&D Systems (Minneapolis, MN) and PGE2 was from
Sigma-Aldrich.
Abs and flow cytometry analysis
The following human Abs were purchased from BD Biosciences (San Jose,
CA): allophycocyanin-CD1a, FITC-CD11c, FITC-CD40, FITC-CD80,
FITC-CD83, FITC-CD86, FITC-HLA-DR, PE-CD14, PE-CD163, FITC-
CD3, and FITC-CD56. For flow cytometry analysis, cells (5 3 105) were
washed in PBS with 0.5% BSA and 0.1% sodium azide, incubated with the
appropriate Ab or isotype controls for 1 h, and then washed and analyzed
by flow cytometry using an LSRII (BD Biosciences).
Generation of DCs
Human PBMCs were isolated from the blood of cancer patients or from
buffy coats of healthy donors (EFS, Besanc¸on, France) by Ficoll-Percoll
density gradient centrifugation. Monocytes were purified from human
PBMCs using CD14 microbeads (Miltenyi Biotec, Bergish Gladbach,
Germany) according to the manufacturer’s recommendations. CD14 purity
was determined using flow cytometry analysis after staining with a PE-
conjugated anti-CD14 Ab (BD Biosciences) and was routinely found to be
.95%. Immature DCs were obtained by incubating monocytes (5 3 105
cells/ml) in RPMI 1640 (BioWhittaker, Basel, Switzerland) supplemented
with 10% FBS and recombinant human GM-CSF (100 ng/ml) and IL-4 (20
ng/ml) (both from PromoCell, Heidelberg, Germany) for 5 d. Day 5 DCs
exhibited a phenotype (low expression of costimulatory molecules such as
CD40, CD80, CD83, CD86, and HLA-DR) and function (high capability
of endocytosis but low IL-12 production and limited ability to induce
T cell proliferation), consistent with those of immature DCs. DC matu-
ration was triggered with LPS (100 ng/ml) or IFN-g (1000 IU/ml) or
a mixture of activators: TNF (20 ng/ml) plus poly(I:C) (50 mg/ml) or IL-1b
(25 ng/ml) plus IL-6 (10 ng/ml) plus TNF-a (50 ng/ml) plus PGE2 (1 mg/
ml) at day 5 for 48 h. Moreover, DC cultures were not contaminated with
conventional cytotoxic cells such as macrophages, T lymphocytes, or NK
cells (Supplemental Fig. 1A).
Cytokine assays
The concentration of IL-12 in cell culture supernatants was determined
using ELISA kits according to the manufacturer’s procedures (Diaclone,
Besanc¸on, France, and Gen-Probe, San Diego, CA).
Transwell assays
The tumor cells were plated (106 cells/well) in 24-well plates. Untreated or
LPS-activated DCs (5 3 106) were deposited in the inner chamber of
a Transwell membrane (0.45 mm pore size) (Dutscher, Brumath, France).
Cytotoxic assays were performed after 48 h.
Cytotoxicity assays
DCs and target tumor cells were cocultured for 48 h. The number of residual
adherent cells was then evaluated by crystal violet staining as previously
described (50). Data are presented as the percentage of relative absorbance
calculated from the formula Atest/Acontrol, where Atest is the absorbance of
tumor cells cultured with DCs in the different conditions, and Acontrol is the
absorbance of tumor cells cultured alone.
Measurement of reactive oxygen and nitrogen species
production by human DCs
The production of reactive oxygen and nitrogen species by cultured human
DCs was evaluated with electron spin resonance (ESR) spectroscopy using
1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (CMH; Noxy-
gen, Elzach, Germany) as the spin probe. CMH is a cell membrane-per-
meable hydroxylamine that can be oxidized by superoxide anions, perox-
ynitrites, and transition metals into a paramagnetic nitroxide (CP•), which
forms a characteristic triplet electron paramagnetic resonance signal with a
half-life of several hours (51–53). Briefly, activated and nonactivated hu-
man DCs (1 3 106) were incubated for 30 min at 37˚C in a 5% CO2 at-
mosphere with 1024 mol/l CMH in 200 ml (pH 7.4) ESR Krebs-HEPES
buffer containing 5 3 1026 mol/l diethyldithiocarbamate and 2.5 3 1025
mol/l desferrioxamine as transition metal chelators, as described elsewhere
(53). After incubation, the cells and medium were immediately frozen in
liquid nitrogen in polyethylene tubes and kept in liquid nitrogen until
measurement. ESR spectra were recorded at 100˚K using a Bruker EMX-
100 spectrometer (Bruker, Wissembourg, France). ESR spectra were ob-
tained using the following instrument settings: center field, 3330.2 g-
factor; sweep width, 100 g-factor; microwave frequency, 9.378 GHz; mi-
crowave power, 20 mW; modulation amplitude, 5 g-factor; conversion
time, 40.96 ms; time constant, 327.68 ms; receiver gain, 1 3 106. The
amplitude of center field anisotropic signal was measured (arbitrary units)
to determine CP• nitroxide formation in activated or nonactivated human
DCs as well as in buffer alone.
Annexin V/propidium iodide
The percentage of apoptotic cells and necrotic cells was determined by
using an FITC-conjugated Annexin VApoptosis Detection Kit I according
to the manufacturer’s recommendations (BD Biosciences).
T lymphocyte proliferation
T lymphocytes were obtained from buffy coats by using a Pan T Cell
Isolation Kit (Miltenyi Biotec). T cells were then stained using a CellTrace
Violet cell proliferation kit according to the manufacturer’s procedure
(Invitrogen, Carlsbad, CA). Labeled cells (1 3 105 cells/well) were
cocultured with DCs (1 3 104) and cell division was detected by flow
cytometry and analyzed by ModFit software after 5 d, as indicated by the
manufacturer (Verity Software House, Topsham, ME).
Statistical analyses
Unless specified, all experiments were reproduced at least three times and
performed on samples from at least three different patients or healthy
donors. Paired t tests were used to compare the different groups. When
more than two groups were compared at the same time, we used repeated
measures ANOVA tests. Results were considered statistically significant
for p , 0.05. Analysis was performed with GraphPad Prism.
Results
LPS induces human monocyte-derived DC cytotoxic activity
We have previously reported that in rats or mice, DC killing acti-
vity can be triggered by the TLR4 ligand LPS (9, 19). To eva-
luate whether similar activation conditions may induce the cyto-
toxic potential of ex vivo-generated human monocyte-derived
DCs, cells were exposed on day 5 to the indicated TLR ligands.
Our results indicate that LPS was the only TLR agonist capable of
triggering DC killing activity (Fig. 1A). LPS-activated day 5 DCs
were able to kill several human tumor cell lines (HT29, MCF7,
HeLa, HCT116, SW480) and some nonmalignant cells (Fig. 1B).
Importantly, the viability of total T lymphocytes was minimally
affected after culture with LPS-activated day 5 DCs (Sup-
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plemental Fig. 1B). Cells obtained after 3 d culture (early in the
differentiation process toward DCs) did not exhibit significant
tumoricidal activity after LPS activation (Supplemental Fig. 1C).
Interestingly, even low concentrations of LPS were sufficient to
trigger the cytotoxic function of DCs with a minimum optimal
concentration between 0.01 and 0.1 mg/ml (Fig. 1C). A direct
cytotoxic effect of LPS on tumor cells was excluded, as the sur-
vival of tumor cells was not affected by exposure to the TLR4
agonist for extensive periods of time (Supplemental Fig. 2A).
Moreover, the pretreatment of tumor cells with LPS did not sen-
sitize them to DC-mediated cytotoxicity (Supplemental Fig. 2B).
Additionally, the results depicted in Fig. 1D indicate that the
elimination of tumor cells was dependent on the effector DC/
target tumor cell ratio.
The maturation state of cytotoxic DCs remains a subject of
controversy. To address this issue, we investigated the cytotoxic
potential of day 5 DCs and day 7 DCs that had been matured from
day 5 to day 7 with different reagents such as LPS, IFN-g, TNF-a
plus poly(I:C), or IL-1b plus IL-6 plus TNF-a plus PGE2 (Sup-
plemental Fig. 3A). These day 7 DCs were activated with LPS and
cultured for 48 h with tumor cells, and then survival of the tumor
cells was assessed. The data presented in Fig. 1E indicate that LPS
failed to trigger the killing activity of day 7 mature DCs regardless
of the maturation mixture used to induce DC maturation (Fig. 1E).
Only immature day 5 DCs were capable of triggering tumor cell
death after activation with LPS (Fig. 1E). We therefore focused
our investigation on the killing properties of LPS-activated day
5 monocyte-derived DCs (hereafter referred to as hKDCs) from
healthy donors and from cancer patients.
hKDCs generated from cancer patient blood monocytes exhibit
cytotoxic activity against tumor cells
The inhibition of DCs by tumors and their maintenance at a non-
functional stage are two of the numerous mechanisms used by
cancer cells to escape the antitumor response. These “tolerogenic”
DCs, typically characterized by an immature or semimature
phenotype, are capable of anergizing effector T lymphocytes and/
or driving the differentiation of immunosuppressive Foxp3+ reg-
ulatory T cells (54, 55). It was therefore fundamental and clini-
cally relevant to determine whether the tumoricidal activity of
FIGURE 1. Killing activity of monocyte-derived DCs from healthy donors. A, HT29 tumor cells were cultured alone (Control) or with day 5 monocyte-
derived DCs (DC/tumor cell ratio of 5:1) with or without (Medium) the indicated TLR ligands: TLR4L, LPS (100 ng/ml); TLR5L, flagellin (100 ng/ml);
TLR7L, gardiquimod (1 mg/ml); TLR3L, poly(I:C) (10 mg/ml); TLR9L, CpG (1 mg/ml); and TLR1,2,6L, PamCys3SK4, (1 mg/ml). DC killing was
evaluated after 48 h as reported (9, 19). *p , 0.05, **p , 0.005 when compared with tumor cells cultured in the absence of DCs (Control) or in the
presence of nonactivated DCs (Medium). B, Day 5 DCs were added to the indicated cancer cell lines at a DC/tumor cell ratio of 5:1 for 48 h in the absence
(DC) or presence of LPS (100 ng/ml) (DC + LPS). Tumor cell viability was determined. *p , 0.05, **p , 0.005 when compared with tumor cells cultured
in DCs in the absence of LPS. C, HT29 tumor cells were cultured for 48 h with day 5 monocyte-derived DCs at a DC/tumor cell ratio of 5:1 in the presence
of LPS at the indicated concentrations. Tumor cell survival was determined as described in Materials and Methods. D, Day 5 monocyte-derived DCs were
cultured for 48 h with HT29 tumor cells in the presence of LPS at the indicated effector (DCs)/target (HT29 tumor cells) ratios and killing of tumor cells
was evaluated. E, HT29 tumor cells were cultured for 48 h with day 5 immature monocyte-derived DCs (DC D5) or with day 7 activated DCs (DC D7) in
the presence or absence of LPS. Day 7 mature DCs were obtained after exposure to different maturation stimuli such as LPS (D7 LPS), IFN-g (D7 IFN),
TNF-a plus poly(I:C) (D7 TNF + PolyI:C), and IL-1b plus IL-6 plus TNF-a plus PGE2 (DC D7 cytokine mixture). Tumor cell viability was then assessed.
For all panels, data are representative of the results obtained with monocyte-derived DCs from 12 different healthy donors.
The Journal of Immunology 2777
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DCs generated from cancer patients was impaired. Monocyte-
derived DCs generated from 10 patients with stage IV cancers
(lung and colon cancers or lymphomas) were characterized by the
same immature phenotype as DCs from healthy volunteers (Sup-
plemental Fig. 3Aa, 3Ab). Upon LPS stimulation, DCs generated
from cancer patients or healthy donors exhibited a similar mature
phenotype and functional properties (Supplemental Fig. 3Ac–f,
Supplemental Fig. 3B) and significant cytotoxic activity against
tumor cells (40–80%) when activated with LPS (Fig. 2A). These
results therefore indicate that the tumor killing ability of DCs
generated from individuals with stage IV cancer is similar to that
in DCs from healthy volunteers (Fig. 2B).
hKDC cytotoxic activity depends on peroxynitrite
We next investigated the mechanism underlying hKDC cytotox-
icity. We first determined that the tumoricidal activity of hKDCs
was dependent on direct cell–cell contact, as separation from their
targets by a microporous membrane prevented killing of cancer
cells (Fig. 3A). Death receptor ligands such as TRAIL or FasL
have been reported to play a role in the cytototoxic activity of DCs
(26, 32, 35, 36, 38, 43–46, 48, 49). We therefore evaluated
whether the tumor killing activity of hKDCs was dependent on
similar processes. Our results indicate that hKDCs were capable
of eliminating tumor cell lines that are resistant to TNF, TRAIL,
or FasL (data not shown). Consistent with these results, LPS-
activated day 5 DCs did not secrete TRAIL or FasL (data not
shown). In line with this result, annexin V and propidium iodide
staining indicated that hKDCs induced the necrosis of tumor cells
as evidenced by early plasma membrane disruption (Fig. 3B).
Consistent with these results, z-VAD-fmk, a broad-spectrum cas-
pase inhibitor, failed at inhibiting hKDC-induced tumor cell death,
thus excluding a conventional apoptotic-related process (Fig. 3C).
We and others have previously reported that NO or peroxyni-
trites represent critical effector molecules required for the tumori-
cidal activity of both rat and mouse DCs (9, 12, 19, 56). To define
whether these cytotoxic products may also play a role in tumor
cell killing by hKDCs, we analyzed reactive oxygen species
production by these killer cells using ESR spectroscopy. ESR
spectroscopy is one of the few techniques that allows the direct
measurement of free radical species. However, most biological
reactive oxygen and nitrogen species of interest are too short-lived
to be measured directly with ESR spectroscopy. Hydroxylamine
spin probes such as CMH can be oxidized by superoxide anion
or peroxynitrites, giving rise to a more stable long-lived ESR-
detectable CP• nitroxide. This allows the detection of these un-
stable species in cell cultures or isolated organs (57, 58). Our
results indicate that both immature (day 5) and mature (day 7)
DCs oxidize CMH into CP• in a time-dependent manner. How-
ever, after 6 h stimulation with LPS, immature day 5 DCs pro-
duced a significantly increased reactive oxygen and nitrogen spe-
cies quantity, a characteristic that was lost in mature day 7 DCs
(Fig. 3D). Moreover, a peroxynitrite inhibitor, FeTPPS, signifi-
cantly abrogated the cytotoxic activity of hKDCs against several
human tumor cells lines (Fig. 3E). We also confirmed that the
cytotoxic activity of monocyte-derived DCs generated from can-
cer patients was inhibited by FeTPPS (Fig. 3F). These results
therefore strongly suggest that hKDCs generated either from
healthy donors or from cancer patients kill tumor cells by a
mechanism involving peroxynitrite production.
hKDCs are capable of capturing tumor cell debris and of
activating tumor-specific T cells
Whether hKDCs that had killed cancer cells are also capable of
presenting tumor Ags and activating specific lymphocytes has re-
mained controversial. A prerequisite for tumor Ag presentation
to T cells is their uptake and processing by DCs. Using GFP-
transfected HT29 tumor cells, we demonstrated that hKDCs were
able to engulf tumor fragments from the tumor cells they had
killed (Fig. 4A). Additionally, after tumor cell killing in presence
of LPS, hKDCs (generated from healthy donors or cancer pa-
tients) exhibited a phenotype consistent with that of mature DCs
(Fig. 4B). Following killing and the uptake of tumor cell frag-
ments, these hKDCs retained their functional properties, as they
were capable of inducing the proliferation of autologous T lym-
phocytes (Fig. 4C). Moreover, using the human melanoma cell
line T1, we demonstrated that after killing cancer cells, KDCs
were capable of inducing the activation of the tumor Ag (Melan-
A25–36)-specific human CD8
+ T cell clone (Fig. 4D). These results
thus indicate that hKDCs generated ex vivo from healthy volun-
teers or cancer patients that had killed tumor cells are efficient at
presenting tumor Ag from the cancer cells they have killed.
Discussion
We have previously reported that KDCs can be generated from rat
(19) and mouse bone marrow (9). In the present study we provide
evidence that human peripheral blood monocytes from both
healthy individuals and, more clinically relevant, from patients
with advanced cancer can also be driven to differentiate into po-
tent killer DCs. The killing mechanism mediated by these hKDCs
involves the production of peroxynitrites. After killing cancer
cells, hKDCs are capable of capturing necrotic tumor cells and of
differentiating into activated and fully functional APCs that pro-
duce IL-12, express high levels of HLA-DR and costimulatory
molecules, and induce T cell proliferation. Moreover, these ex
FIGURE 2. Monocyte-derived DCs generated from cancer patients can
be differentiated into potent hKDCs. A, HT29 tumor cells were cultured
alone (Medium) or with monocyte-derived DCs generated from 10 cancer
patients (1–10) (DC/tumor cell ratio of 5:1) in the presence (DC + LPS) or
absence of LPS (DC). Tumor cell viability was determined after 48 h. *p,
0.05 when compared with tumor cells cultured in absence of DCs (Me-
dium) or with nonactivated DCs (DC). B, The cytotoxic activity of
monocyte-derived DCs generated from 10 cancer patients was compared
with the killing potential of monocyte-derived DCs generated from 12
healthy donors. The values represent the percentage of viable HT29 tumor
cells after 48 h coculture with LPS-activated, monocyte-derived DCs from
healthy donors or from cancer patients.
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vivo-generated hKDCs are capable of activating tumor Ag-
specific CTLs, which strongly advocates for their therapeutic
use in cancer patients. To facilitate the clinical application of
hKDCs, we also demonstrated that KDCs could be generated in
serum-free medium (Supplemental Fig. 4).
The cytotoxic activity of human immature peripheral blood
monocyte-derived DCs has already been reported (27, 35, 37, 45,
46), but no or only a low killing activity at an E:T ratio of 5:1 was
observed. Additionally, in these studies, LPS was used at high
concentrations, ranging from 5 (27, 43) to 10 mg/ml (37). In
FIGURE 3. Human monocyte-derived DC killing activity depends on peroxynitrites. A, HT29 cells were cultured alone (Medium) or with monocyte-
derived DCs from healthy donors in the presence (DC + LPS) or not of LPS (DC). The cells were cultured together (Control) or separated by a Transwell
insert (Transwell). Tumor cell killing was determined after 48 h. B, HT29 tumor cells were cultured alone (Medium), with LPS, with day 5 monocyte-
derived DCs from healthy donors with (DC + LPS), or without LPS (DC). After 48 h, the cells were stained with CD1a Ab and with annexin V-FITC/
propidium iodide (PI). The percentage of PI2annexin V+ (apoptotic) or PI+annexin V+ (necrotic) tumor cells was determined after gating on CD1a-negative
HT29 tumor cells. C, HT29 tumor cells were cultured alone (Medium), with LPS (100 ng/ml) (LPS), with day 5 monocyte-derived DCs (DC), with DCs in
the presence of LPS (DC + LPS), or with DCs in the presence of LPS plus z-VAD-fmk (40 mM) (DC/tumor cell ratio of 5:1). Tumor cell survival was
determined after 48 h. D, Production of reactive oxygen species by nonactivated or LPS-activated human monocyte-derived DCs was determined by ESR.
CMH was used as the spin probe. Day 5 monocyte-derived DCs from healthy donors were cultured with (DC + LPS) or without LPS (DC) for 6 h. Activated
and nonactivated human DCs (2 3 106) were harvested and incubated with 1 mmol/l CMH. The amplitude of center field anisotropic signal was quantified
in arbitrary units to determine CP• nitroxide formation in LPS-activated or nonactivated human DCs at days 5 and 7. This experiment was done three times
with DCs from three different healthy donors and from three cancer patients. *p, 0.05, **p, 0.005. E, HT29 tumor cells were cultured alone (Control) or
with day 5 monocyte-derived DCs from healthy donors (DC): without LPS (Medium), with LPS, or with LPS and FeTPPS (50 mM) (LPS + FeTPPS).
Tumor cell viability was determined after 48 h. F, Different human tumor cell lines (HT29, HeLa, HCT116, SW480) were cocultured with LPS-activated
human monocyte-derived DCs from healthy volunteers or from cancer patients in the presence (DC + LPS + FeTPPS) or absence (DC + LPS) of FeTPPS
(50 mM) (DC/tumor cell ratio of 5:1). Tumor cell viability was determined after 48 h. Similar results were obtained with DCs generated from six healthy
donors and four cancer patients. *p , 0.05 when compared with tumor cells cultured with activated DCs in the absence of FeTPPS.
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contrast to these high concentrations, we now report that LPS
induces hKDC killing activity even at doses as low as 10 ng/ml.
The mechanisms underlying KDC-mediated cytotoxic function
have been related to death receptors and their ligands (25–27, 29,
32–36, 42, 44, 46, 47). Our results indicate that hKDCs induce
tumor cell necrosis by a process that is independent of the above-
mentioned mechanisms of cytotoxicity. By using the ESR tech-
nique and specific inhibitors, we identified peroxynitrites as the
primary molecule responsible for KDC tumoricidal function. The
inhibition of KDC killing activity by the peroxynitrite catalyst
FeTPPS (59–63) confirmed the primary role of these molecules.
Importantly, although the mechanism of cytotoxicity used by these
hKDCs is not specific to tumor cells and may affect normal cell
survival, we confirmed that no significant killing of T lymphocytes
was detectable in the presence of hKDCs. This can be explained
by the fact that T lymphocyte killing might be a minor phenom-
enon compared with the high proliferation rate of T cells induced
by these DCs. Another explanation may stem from the fact that the
high levels of proinflammatory cytokines produced by hKDCs can
support T cell survival by activating anti-apoptotic mechanisms
that render T lymphocytes resistant to DC-mediated cytotoxicity.
In support of this hypothesis, recent studies have reported on
cytokine driven upregulation of Bcl2 or related anti-apoptotic
molecules in subsets of effector and memory T cells, allowing
them to survive (64–66).
Whether KDCs can be generated from cancer patients has not
been previously elucidated. This is a relevant question insofar as the
tumor microenvironment is able to suppress many aspects of the
anti-cancer immune response to escape from recognition by the
immune system (67, 68). One of the mechanisms of tumor-induced
immunosuppression consists in inhibiting the ability of DC pre-
cursors to differentiate into functional cells (5, 68, 69). We
FIGURE 4. hKDCs exhibit the phenotypical and
functional characteristics of mature activated APCs
after killing of tumor cells. A, GFP-transfected HT29
tumor cells were cultured with day 5 monocyte-de-
rived DCs (DC) or with LPS (DC + LPS) for 72 h. The
cells were then stained with CD1a Ab and analyzed by
flow cytometry for GFP expression. Representative
data of three experiments performed with DCs from
healthy donors are shown. B, Upper histograms,
Phenotype of day 5 monocyte-derived DCs (dark
gray) compared with mature DCs (light gray) or
hKDCs from healthy patient (black line). Lower his-
tograms, Phenotype of day 5 monocyte-derived DCs
(full gray) compared with hKDCs from healthy patient
(black line) or from cancer patients (red line). hKDCs
were collected from a 48-h culture with HT29 tumor
cells and LPS. Cells were stained with the indicated
Ab and analyzed by flow cytometry. C, Autologous T
lymphocyte proliferation was assessed using a Cell-
Trace Violet cell proliferation kit as described in
Materials and Methods. CellTrace Violet-labeled pu-
rified T cells were cocultured with day 5 immature
DCs without activator (T + DC), with LPS (100 ng/
ml) (T + DC + LPS), with HT29 tumor cells (T + DC
[tu]), or with HT29 tumor cells in the presence of LPS
(T + DC [LPS + tu]) (DC/T cell ratio of 1:10). Non-
activated T cells were used as a negative control, and
T cells stimulated with anti-CD3/anti-CD28 T cell
expansion beads were used as a positive control
(T cells). The T cell proliferation index (Pi) was de-
fined after 5 d T cell/DC cocultures using ModFit
software. B and C, Representative results from three
experiments performed with DCs from three differ-
ent healthy donors and from three different cancer
patients are shown. D, Immature day 5 DCs were
cultured with T1 melanoma cell line in the presence or
absence of LPS (100 ng/ml). After 48 h, DCs were
harvested from these cocultures and plated with anti-
T1 CD8+ T cells (CTL clone specific for Melan-A25–36
peptide) for an additional 4 h (DC/T cell ratio of 5:1).
TNF-a production by CTLs was measured using a
TNF-a ELISA kit.
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therefore reasoned that the tumor killing activity of DCs generated
from cancer patient monocytes may be impaired. Our results in-
dicate that KDCs generated from all the cancer patients evaluated
in this study were able to kill tumor cells, indicating that this
cytotoxic potential was not inhibited by the tumor environment.
Moreover, whatever the type of cancer, hematological or solid
tumors, hKDCs from cancer patients were as cytotoxic as those
from healthy donors. This is a clinically important finding that
opens new perspectives for the use of autologous hKDCs in cancer
patients. The use of hKDCs could circumvent extensive ex vivo
manipulations during DC vaccine protocols, such as tumor Ag pre-
paration and loading, and DC activation. Autologous DCs from
cancer patients may be differentiated into hKDCs and activated ex
vivo and then used to kill autologous tumor cells and to acquire
and process released tumor Ag in vitro before being reinjected into
the patient. These novel findings may be relevant for the design of
new improved DC-based vaccines.
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